文献速递心力衰竭与心肌病

恩格列净对射血分数保留心力衰竭患者健康状况和生活质量的影响:EMPEROR-Preserved 试验

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
PubMed 文献 · Circulation · 2021-11-15

EMPEROR-Preserved 试验评估恩格列净对射血分数保留心力衰竭患者健康相关生活质量的影响,并分析临床获益是否随基线健康状况而变化。结果显示,恩格列净降低主要心力衰竭结局风险的作用在基线 KCCQ 评分各三分位组中一致,并显著改善生活质量,效果早期出现且持续至少 1 年。

要点

  • 恩格列净降低心血管死亡或心衰住院风险的作用在基线 KCCQ 各三分位组中一致。
  • 恩格列净显著改善 KCCQ 临床总结评分,12、32、52 周均优于安慰剂。
  • 恩格列净提高 KCCQ 评分改善≥5、≥10、≥15 分的 odds,并降低恶化≥5 分的 odds。

核心结论

  • 在射血分数保留心力衰竭患者中,恩格列净在基线 KCCQ 评分范围内均降低主要心力衰竭结局风险。
  • 恩格列净改善健康相关生活质量,效果早期出现并持续至少 1 年。

研究设计与样本

  • EMPEROR-Preserved 试验的事后分析,评估恩格列净对健康相关生活质量的影响。
  • 使用堪萨斯城心肌病问卷(KCCQ)在基线及 12、32、52 周测量生活质量。
  • 患者按基线 KCCQ 临床总结评分(CSS)三分位分组,分析恩格列净对结局的影响。

主要发现

  • 恩格列净降低心血管死亡或心衰住院风险在各基线 KCCQ-CSS 三分位组一致:<62.5 组 HR 0.83(95%CI 0.69-1.00),62.5-83.3 组 HR 0.70(95%CI 0.55-0.88),≥83.3 组 HR 0.82(95%CI 0.62-1.08);P trend=0.77。
  • 恩格列净组 KCCQ-CSS 较安慰剂显著改善:12 周 +1.03、32 周 +1.24、52 周 +1.50(P<0.01)。
  • 12 周时恩格列净组 KCCQ-CSS 改善≥5 分 OR 1.23(95%CI 1.10-1.37)、≥10 分 OR 1.15(95%CI 1.03-1.27)、≥15 分 OR 1.13(95%CI 1.02-1.26),恶化≥5 分 OR 0.85(95%CI 0.75-0.97)。
  • 32 周和 52 周呈现相似模式,总症状评分和总体总结评分结果一致。

临床怎么用

  • 对于射血分数保留心力衰竭患者,无论基线健康状况如何,均可考虑使用恩格列净以降低心衰结局风险。
  • 恩格列净可改善生活质量,临床决策时可据此与患者沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), we evaluated the efficacy of empagliflozin on health-related quality of life in patients with heart failure with preserved ejection fraction and whether the clinical benefit observed with empagliflozin varies according to baseline health status. METHODS: Health-related quality of life was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline and 12, 32, and 52 weeks. Patients were divided by baseline KCCQ Clinical Summary Score (CSS) tertiles, and the effect of empagliflozin on outcomes was examined. The effect of empagliflozin on KCCQ-CSS, Total Symptom Score, and Overall Summary Score was evaluated. Responder analyses were performed to compare the odds of improvement and deterioration in KCCQ related to treatment with empagliflozin. RESULTS: The effect of empagliflozin on reducing the risk of time to cardiovascular death or heart failure hospitalization was consistent across baseline KCCQ-CSS tertiles (hazard ratio, 0.83 [95% CI, 0.69-1.00], 0.70 [95% CI, 0.55-0.88], and 0.82 [95% CI, 0.62-1.08] for scores <62.5, 62.5-83.3, and ≥83.3, respectively; P trend=0.77). Similar results were seen for total heart failure hospitalizations. Patients treated with empagliflozin had significant improvement in KCCQ-CSS versus placebo (+1.03, +1.24, and +1.50 at 12, 32, and 52 weeks, respectively; P<0.01); similar results were seen for Total Symptom Score and Overall Summary Score. At 12 weeks, patients on empagliflozin had higher odds of improvement ≥5 points (odds ratio, 1.23 [95% CI, 1.10-1.37]), ≥10 points (odds ratio, 1.15 [95% CI, 1.03-1.27]), and ≥15 points (odds ratio, 1.13 [95% CI, 1.02-1.26]) and lower odds of deterioration ≥5 points in KCCQ-CSS (odds ratio, 0.85 [95% CI, 0.75-0.97]). A similar pattern was seen at 32 and 52 weeks, and results were consistent for Total Symptom Score and Overall Summary Score. CONCLUSIONS: In patients with heart failure with preserved ejection fraction, empagliflozin reduced the risk for major heart failure outcomes across the range of baseline KCCQ scores. Empagliflozin improved health-related quality of life, an effect that appeared early and was sustained for at least 1 year. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057951.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Butler, Filippatos, Jamal Siddiqi, et al. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation. 2021. PMID: 34779658. doi:10.1161/CIRCULATIONAHA.121.057812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。